The most commonly reported side effects of ibritumomab include sepsis, meningitis tuberculous, and off label use, based on 1,514 FDA adverse event reports from 2004 to 2025.
Percentages show how often each reaction appears relative to total reports for ibritumomab.
1
Sepsis9.2%139
2
Meningitis Tuberculous8.3%126
3
Off Label Use6.1%92
4
Myelodysplastic Syndrome5.9%90
5
Thrombocytopenia5.5%83
6
Thrombocytopenia5.0%76
7
Progressive Multifocal Leukoencephalopathy5.0%75
8
Neutropenia4.8%72
9
Neutropenia4.5%68
10
Febrile Neutropenia4.2%63
11
Mucosal Inflammation4.0%61
12
Anaemia3.8%57
13
White Blood Cell Count Decreased3.7%56
14
Platelet Count Decreased3.4%52
15
Pancytopenia3.2%48
These are voluntary reports and do not establish that ibritumomab caused these reactions.
Report severity
97.2%Serious1,472 reports
40.5%Hospitalizations613 reports
38.7%Fatal586 reports
Seriousness is determined by the reporter, not by OpenClaim.
Ibritumomab drug interactions
Other drugs that appear in adverse event reports alongside ibritumomab. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
1
Rituximab45.4%687
2
Vincristine-sulfate23.6%357
3
Doxorubicin-hydrochloride22.3%337
4
Etoposide22.1%334
5
Cyclophosphamide20.5%311
6
Prednisone18.3%277
7
Fludarabine-phosphate17.0%257
8
Cytarabine14.1%213
9
Melphalan11.0%166
10
Carboplatin10.6%161
11
Busulfan10.6%160
12
Cisplatin10.2%155
13
Ifosfamide9.9%150
14
Filgrastim7.8%118
15
Bendamustine-hydrochloride7.3%110
Taken alongside
1
Rituximab25.0%378
2
Fludarabine-phosphate10.2%154
3
Etoposide8.9%134
4
Cyclophosphamide7.7%116
5
Cyclosporine7.5%113
6
Melphalan7.2%109
7
Cytarabine6.2%94
8
Carmustine6.1%92
9
Vincristine-sulfate6.0%91
10
Doxorubicin-hydrochloride5.4%82
11
Prednisone4.3%65
12
Dexamethasone4.2%63
13
Methylprednisolone3.4%52
14
Hydrocortisone3.2%49
15
Acetaminophen3.2%48
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
Who reports ibritumomab side effects
26.2% of ibritumomab adverse event reports involve female patients and 40.4% involve male patients. The largest age group is adult at 61%. These figures reflect who reports side effects, not underlying risk.
Sex
Female26.2%
Male40.4%
Unknown33.4%
Age group
< 20.0%
2–112.5%
12–170.0%
18–6461.2%
65+36.4%
What is ibritumomab used for
Conditions and purposes for which patients were taking ibritumomab when the adverse event was reported.
